At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 128 enrolled
Drug / intervention
Tranexamic Acid (TXA) +1 moredrug
Likely dose
Tranexamic Acid (TXA) 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement in Low Energy Hip Fracture Patients?
In Brief
A Phase 2 clinical trial evaluating Tranexamic Acid (TXA) and Placebo for Hip Fractures and Intertrochanteric Fractures. Completed, enrolled 128 participants across 1 site.
Detailed Summary
Intertrochanteric hip fractures typically result in blood loss from the fracture and require surgery that can cause further blood loss. This study is being done to look at a medication called tranexamic acid which may reduce blood loss and the need for blood transfusions associated with surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHip Fractures, Intertrochanteric Fractures
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartApr 2018
Primary CompletionMay 2022
TodayJul 2026
First PostedJun 9, 2017
Enrollment StartApr 2, 2018
Primary CompletionMay 24, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 9.1 years ago
Interventions
Tranexamic Acid (TXA)drug
Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
Placebodrug
Looks exactly like the study drug, but it contains no active ingredient